Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
pBI-4 in HPV16-Positive CIN1 or Persistent HPV16 Infection
NCT07809997Phase 2Not yet recruiting
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Sep 2026
- Primary completion
- Mar 2030
- Countries
- 1
01
Overview
A Phase 2 trial of pBI-4 Vaccine in cervical intraepithelial neoplasia (CIN), human papillomavirus type 16 infection, sponsored by Chang Gung Memorial Hospital. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
pBI-4 Vaccine
03
Conditions
cervical intraepithelial neoplasia (CIN)human papillomavirus type 16 infection
Beyond the preview
Go deeper on NCT07809997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07809997.